MyFinsight
Home
Blog
About
Cash and cash
equivalents
$12,167,136
Prepaid expenses and
other current assets
$1,009,958
(28.95%↑ Y/Y)
Inventories
$288,450
Total current assets
$13,465,544
(1260.95%↑ Y/Y)
Deferred financing costs
$75,000
Total assets
$13,540,544
(1268.53%↑ Y/Y)
Total liabilities and
stockholders equity...
$13,540,544
(1268.53%↑ Y/Y)
Total stockholders
equity (deficit)
$11,757,821
(222.26%↑ Y/Y)
Total liabilities
$1,782,723
(-83.19%↓ Y/Y)
Accumulated deficit
-$31,749,115
(-53.38%↓ Y/Y)
Additional paid-in capital
$43,506,805
(292.73%↑ Y/Y)
Total current
liabilities
$1,686,196
(-84.03%↓ Y/Y)
Forward purchase
agreement liability
$96,527
(95.85%↑ Y/Y)
Common stock 0.0001 par
value 490,000,000...
$129
(-97.40%↓ Y/Y)
Series a convertible
preferred stock, 30,000...
$2
Accounts payable
$972,108
(-28.08%↓ Y/Y)
Accrued expenses
$714,088
(88.82%↑ Y/Y)
Back
Back
Balance Sheet
Aspire Biopharma Holdings, Inc. (ASBPW)
Aspire Biopharma Holdings, Inc. (ASBPW)
source: myfinsight.com